结直肠癌转移机制及靶向药物相关研究进展
Research Progress on Colorectal Cancer Me-tastasis Mechanisms and Targeted Therapy
摘要: 近年来，结直肠癌的发病率和死亡率不断上升，术后复发及转移是导致患者死亡的主要原因。肿瘤微环境通过各种机制参与转移性结直肠癌的发生、发展，因此，研究肿瘤微环境与结直肠癌远处转移的关系有助于寻找肿瘤治疗靶点。本文旨在综述结直肠癌转移机制的研究进展，并重点关注靶向药物在治疗结直肠癌转移中的应用。
Abstract: In recent years, the incidence and mortality of colorectal cancer have been increasing, with postop-erative recurrence and metastasis being the main causes of patient death. The tumor microenvi-ronment is involved in the occurrence and development of metastatic colorectal cancer through various mechanisms. Therefore, studying the relationship between the tumor microenvironment and distant metastasis of colorectal cancer is helpful in identifying therapeutic targets for tumor treatment. This article aims to provide an overview of the research progress on the mechanisms of colorectal cancer metastasis, with a focus on the application of targeted therapy in the treatment of colorectal cancer metastasis.
文章引用：王玥瑶. 结直肠癌转移机制及靶向药物相关研究进展[J]. 临床医学进展, 2024, 14(1): 959-965. https://doi.org/10.12677/ACM.2024.141137

参考文献

[1] Adam, R., De Gramont, A., Figueras, J., Guthrie, A., Kokudo, N., Kunstlinger, F., et al. (2012) The Oncosurgery Ap-proach to Managing Liver Metastases from Colorectal Cancer: A Multidisciplinary International Consensus. Oncologist, 17, 1225-1239. [Google Scholar] [CrossRef] [PubMed]
[2] Sung, J.J., Lau, J.Y., Goh, K.L., Leung, W.K. and Asia Pacific Working Group on Colorectal Cancer (2005) Increasing Incidence of Colorectal Cancer in Asia: Impli-cations for Screening. The Lancet Oncology, 6, 871-876. [Google Scholar] [CrossRef] 
[3] Ciardiello, F., Ciardiello, D., Martini, G., Napolitano, S., Tabernero, J. and Cervantes, A. (2022) Clinical Management of Metastatic Colorectal Cancer in the Era of Precision Medicine. CA: A Cancer Journal for Clinicians, 72, 372-401. [Google Scholar] [CrossRef] [PubMed]
[4] Biller, L.H. and Schrag, D. (2021) Diagnosis and Treatment of Metastatic Colorectal Cancer: A Review. JAMA, 325, 669-685. [Google Scholar] [CrossRef] [PubMed]
[5] Siegel, R.L., Miller, K.D., Wagle, N.S. and Jemal, A. (2023) Cancer Statistics, 2023. CA: A Cancer Journal for Clinicians, 73, 17-48. [Google Scholar] [CrossRef] [PubMed]
[6] Gallagher, D.J. and Kemeny, N. (2010) Metastatic Colorectal Cancer: From Improved Survival to Potential Cure. Oncology, 78, 237-248. [Google Scholar] [CrossRef] [PubMed]
[7] Riedesser, J.E., Ebert, M.P. and Betge, J. (2022) Precision Medicine for Metastatic Colorectal Cancer in Clinical Practice. Therapeu-tic Advances in Medical Oncology, 14, 1-25. [Google Scholar] [CrossRef] [PubMed]
[8] Brodsky, F.M. (1988) Monoclonal Antibodies as Magic Bullets. Pharmaceutical Research, 5, 1-9. [Google Scholar] [CrossRef] 
[9] 顾艳宏, 姜争, 李健, 邱萌. 结直肠癌靶向治疗中国专家共识[J]. 中华普通外科学文献(电子版), 2023, 17(1): 1-8.
[10] Chen, Y.F., Yu, Z.L., Lv, M.Y., Cai, Z.R., Zou, Y.F., Lan, P., et al. (2021) Cancer-Associated Fibroblasts Impact the Clinical Outcome and Treatment Response in Colorectal Can-cer via Immune System Modulation: A Comprehensive Genome-Wide Analysis. Molecular Medicine, 27, Article No. 139. [Google Scholar] [CrossRef] [PubMed]
[11] Bhat, A.A., Nisar, S., Singh, M., Ashraf, B., Masoodi, T., Prasad, C.P., et al. (2022) Cytokine- and Chemokine-Induced Inflammatory Colorectal Tumor Microenvironment: Emerging Avenue for Targeted Therapy. Cancer Communications, 42, 689-715. [Google Scholar] [CrossRef] [PubMed]
[12] Balkwill, F.R., Capasso, M. and Hagemann, T. (2012) The Tumor Micro-environment at a Glance. Journal of Cell Science, 125, 5591-5596. [Google Scholar] [CrossRef] [PubMed]
[13] Jin, M.Z. and Jin, W.L. (2020) The Updated Landscape of Tumor Microenvironment and Drug Repurposing. Signal Transduction and Targeted Therapy, 5, Article No.166. [Google Scholar] [CrossRef] [PubMed]
[14] Shi, Y., Gao, W., Lytle, N.K., Huang, P., Yuan, X., Dann, A.M., et al. (2019) Targeting LIF-Mediated Paracrine Interaction for Pancreatic Cancer Therapy and Monitoring. Nature, 569, 131-135. [Google Scholar] [CrossRef] [PubMed]
[15] Straussman, R., Morikawa, T., Shee, K., Barzily-Rokni, M., Qian, Z.R., et al. (2012) Tumour Micro-Environment Elicits Innate Resistance to RAF Inhibitors through HGF Secretion. Na-ture, 487, 500-504. [Google Scholar] [CrossRef] [PubMed]
[16] Bruzzese, F., Hägglöf, C., Leone, A., Sjöberg, E., Roca, M.S., Kiflema-riam, S., et al. (2014) Local and Systemic Protumorigenic Effects of Cancer-Associated Fibroblast-Derived GDF15. Cancer Research, 74, 3408-3417. [Google Scholar] [CrossRef] 
[17] Sahai, E., Astsaturov, I., Cukierman, E., DeNardo, D.G., Egeblad, M., Evans, R.M., et al. (2020) A Framework for Advancing Our Understanding of Cancer-Associated Fibro-blasts. Nature Reviews Cancer, 20, 174-186. [Google Scholar] [CrossRef] [PubMed]
[18] Zhong, B., Cheng, B., Huang, X., Xiao, Q., Niu, Z., Chen, Y.F., et al. (2021) Colorectal Cancer-Associated Fibroblasts Promote Metastasis by Up-Regulating LRG1 through Stromal IL-6/STAT3 Signaling. Cell Death & Disease, 13, Article No. 16. [Google Scholar] [CrossRef] [PubMed]
[19] Mao, X., Xu, J., Wang, W., Liang, C., Hua, J., Liu, J., et al. (2021) Crosstalk between Cancer-Associated Fibroblasts and Immune Cells in the Tumor Microenvironment: New Findings and Future Perspectives. Molecular Cancer, 20, Article No. 131. [Google Scholar] [CrossRef] [PubMed]
[20] Cassetta, L. and Pollard, J.W. (2020) Tumor-Associated Macro-phages. Current Biology, 30, R246-R248. [Google Scholar] [CrossRef] [PubMed]
[21] Larionova, I., Cherdyntseva, N., Liu, T., Patysheva, M., Rakina, M. and Kzhyshkowska, J.J.O. (2019) Interaction of Tumor-Associated Macrophages and Cancer Chemotherapy. OncoIm-munology, 8, e1596004. [Google Scholar] [CrossRef] 
[22] Zhu, X., Liang, R., Lan, T., Ding, D., Huang, S., Shao, J., et al. (2022) Tumor-Associated Macrophage-Specific CD155 Contributes to M2-Phenotype Transition, Immunosuppres-sion, and Tumor Progression in Colorectal Cancer. Journal for Immunotherapy of Cancer, 10, e004219. [Google Scholar] [CrossRef] [PubMed]
[23] Wang, H., Tian, T. and Zhang, J. (2021) Tumor-Associated Macro-phages (TAMs) in Colorectal Cancer (CRC): From Mechanism to Therapy and Prognosis. International Journal of Mo-lecular Sciences, 22, Article 8470. [Google Scholar] [CrossRef] [PubMed]
[24] Fu, L.Q., Du, W.L., Cai, M.H., Yao, J.Y., Zhao, Y.Y. and Mou, X.Z. (2020) The Roles of Tumor-Associated Macrophages in Tumor Angiogenesis and Metastasis. Cellular Immunology, 353, Article ID: 104119. [Google Scholar] [CrossRef] [PubMed]
[25] Zhao, S., Mi, Y., Guan, B., Zheng, B., Wei, P., Gu, Y., et al. (2020) Tumor-Derived Exosomal miR-934 Induces Macrophage M2 Polarization to Promote Liver Metastasis of Colo-rectal Cancer. Journal of Hematology & Oncology, 13, Article No. 156. [Google Scholar] [CrossRef] [PubMed]
[26] Zhang, N., Ng, A.S., Cai, S., Li, Q., Yang, L. and Kerr, D. (2021) Novel Therapeutic Strategies: Targeting Epithelial-Mesenchymal Transition in Colorectal Cancer. The Lancet On-cology, 22, e358-e368. [Google Scholar] [CrossRef] 
[27] Dongre, A. and Weinberg, R.A. (2019) New Insights into the Mechanisms of Epithelial-Mesenchymal Transition and Implications for Cancer. Nature Reviews Molecular Cell Bi-ology, 20, 69-84. [Google Scholar] [CrossRef] [PubMed]
[28] Fumagalli, A., Oost, K.C., Kester, L., Morgner, J., Bornes, L., Bruens, L., et al. (2020) Plasticity of Lgr5-Negative Cancer Cells Drives Metastasis in Colorectal Cancer. Cell Stem Cell, 26, 569-578.E7. [Google Scholar] [CrossRef] [PubMed]
[29] Lin, D., Shen, L., Luo, M., Zhang, K., Li, J., Yang, Q., et al. (2021) Circulating Tumor Cells: Biology and Clinical Significance. Signal Transduction and Targeted Therapy, 6, Article No. 404. [Google Scholar] [CrossRef] [PubMed]
[30] Leblanc, R. and Peyruchaud, O. (2016) Metastasis: New Func-tional Implications of Platelets and Megakaryocytes. Blood, 128, 24-31. [Google Scholar] [CrossRef] [PubMed]
[31] Mizuno, R., Kawada, K., Itatani, Y., Ogawa, R., Kiyasu, Y. and Sakai, Y. (2019) The Role of Tumor-Associated Neutrophils in Colorectal Cancer. International Journal of Molecu-lar Sciences, 20, Article 529. [Google Scholar] [CrossRef] [PubMed]
[32] Gong, L., Cai, Y., Zhou, X. and Yang, H. (2012) Activated Platelets Interact with Lung Cancer Cells through P-Selectin Glycoprotein Ligand-1. Pathology & Oncology Research, 18, 989-996. [Google Scholar] [CrossRef] [PubMed]
[33] Brodt, P. (2016) Role of the Microenvironment in Liver Metasta-sis: From Pre- to Prometastatic Niches. Clinical Cancer Research, 22, 5971-5982. [Google Scholar] [CrossRef] 
[34] Auguste, P., Fallavollita, L., Wang, N., Burnier, J., Bikfalvi, A. and Brodt, P. (2007) The Host Inflammatory Response Promotes Liver Metastasis by Increasing Tumor Cell Arrest and Extravasation. The American Journal of Pathology, 170, 1781-1792. [Google Scholar] [CrossRef] [PubMed]
[35] Khatib, A.M., Auguste, P., Fallavollita, L., Wang, N., Samani, A., Kontogiannea, M., et al. (2005) Characterization of the Host Proinflammatory Response to Tumor Cells during the Initial Stages of Liver Metastasis. The American Journal of Pathology, 167, 749-759. [Google Scholar] [CrossRef] 
[36] Benedicto, A., Herrero, A., Romayor, I., Marquez, J., Smedsrød, B., Olaso, E., et al. (2019) Liver Sinusoidal Endothelial Cell ICAM-1 Mediated Tumor/Endothelial Crosstalk Drives the Development of Liver Metastasis by Initiating Inflammatory and Angiogenic Responses. Scientific Reports, 9, Article No. 13111. [Google Scholar] [CrossRef] [PubMed]
[37] 郭慧娴, 周慧玲, 朱晓蔚, 于鸿. 结直肠癌分子靶向治疗的研究进展[J]. 癌症进展, 2022, 20(19): 1950-1953.
[38] Riechelmann, R. and Grothey, A. (2017) Antiangiogenic Therapy for Refractory Colorectal Cancer: Current Options and Future Strategies. Therapeutic Advances in Medical On-cology, 9, 106-126. [Google Scholar] [CrossRef] [PubMed]
[39] Rosen, L.S., Jacobs, I.A. and Burkes, R.L. (2017) Bevacizumab in Colorectal Cancer: Current Role in Treatment and the Potential of Biosimilars. Targeted Oncology, 12, 599-610. [Google Scholar] [CrossRef] [PubMed]
[40] Cunningham, D., Lang, I., Marcuello, E., Lorusso, V., Ocvirk, J., Shin, D.B., et al. (2013) Bevacizumab plus Capecitabine versus Capecitabine Alone in Elderly Patients with Previously Untreated Metastatic Colorectal Cancer (AVEX): An Open-Label, Randomised Phase 3 Trial. The Lancet Oncology, 14, 1077-1085. [Google Scholar] [CrossRef] 
[41] Tebbutt, N.C., Wilson, K., Gebski, V.J., Cummins, M.M., Zannino, D., van Hazel, G.A., et al. (2010) Capecitabine, Bevacizumab, and Mitomycin in First-Line Treatment of Meta-static Colorectal Cancer: Results of the Australasian Gastrointestinal Trials Group Randomized Phase III MAX Study. Journal of Clinical Oncology, 28, 3191-3198. [Google Scholar] [CrossRef] 
[42] Folprecht, G., Pericay, C., Saunders, M.P., Thomas, A., Lopez Lopez, R., Roh, J.K., et al. (2016) Oxaliplatin and 5-FU/Folinic Acid (Modified FOLFOX6) with or without Aflibercept in First-Line Treatment of Patients with Metastatic Colorectal Cancer: The AFFIRM Study. Annals of Oncology, 27, 1273-1279. [Google Scholar] [CrossRef] [PubMed]
[43] Chan, D.L.H., Segelov, E., Wong, R.S., Smith, A., Herbertson, R.A., Li, B.T., et al. (2017) Epidermal Growth Factor Receptor (EGFR) Inhibitors for Metastatic Colorectal Cancer. The Cochrane Database of Systematic Reviews, 6, CD007047. [Google Scholar] [CrossRef] 
[44] Mendelsohn, J., Prewett, M., Rockwell, P. and Goldstein, N.I. (2015) CCR 20th Anniversary Commentary: A Chimeric Antibody, C225, Inhibits EGFR Activation and Tumor Growth. Clinical Cancer Research, 21, 227-229. [Google Scholar] [CrossRef] 
[45] Yarom, N. and Jonker, D.J. (2011) The Role of the Epider-mal Growth Factor Receptor in the Mechanism and Treatment of Colorectal Cancer. Discovery Medicine, 11, 95-105.
[46] Richman, S.D., Southward, K., Chambers, P., Cross, D., Barrett, J., Hemmings, G., et al. (2016) HER2 Overexpression and Amplification as a Potential Therapeutic Target in Colorectal Cancer: Analysis of 3256 Patients En-rolled in the QUASAR, FOCUS and PICCOLO Colorectal Cancer Trials. The Journal of Pathology, 238, 562-570. [Google Scholar] [CrossRef] [PubMed]
[47] Nowak, J.A. (2020) HER2 in Colorectal Carcinoma: Are We There Yet? Surgical Pathology Clinics, 13, 485-502. [Google Scholar] [CrossRef] [PubMed]
[48] Yonesaka, K., Zejnullahu, K., Okamoto, I., Satoh, T., Cappuzzo, F., Souglakos, J., et al. (2011) Activation of ERBB2 Signaling Causes Resistance to the EGFR-Directed Therapeutic Anti-body Cetuximab. Science Translational Medicine, 3, 99ra86. [Google Scholar] [CrossRef] [PubMed]
[49] 杨国华. 结直肠癌分子靶向治疗研究进展[J]. 中国老年学杂志, 2021, 41(22): 5164-5168.
[50] Huang, W., Chen, Y., Chang, W., Ren, L., Tang, W., Zheng, P., et al. (2022) HER2 Positivity as a Biomarker for Poor Prognosis and Unre-sponsiveness to Anti-EGFR Therapy in Colorectal Cancer. Journal of Cancer Research and Clinical Oncology, 148, 993-1002. [Google Scholar] [CrossRef] [PubMed]
[51] Sanz-Garcia, E., Argiles, G., Elez, E. and Tabernero, J. (2017) BRAF Mutant Colorectal Cancer: Prognosis, Treatment, and New Perspectives. Annals of Oncology, 28, 2648-2657. [Google Scholar] [CrossRef] [PubMed]
[52] Kopetz, S., Desai, J., Chan, E., Hecht, J.R., O’Dwyer, P.J., Maru, D., et al. (20150 Phase II Pilot Study of Vemurafenib in Patients with Metastatic BRAF-Mutated Colorectal Cancer. Journal of Clinical Oncology, 33, 4032-4038.[CrossRef] 
[53] Zhao, B., Wang, L., Qiu, H., Zhang, M., Sun, L., Peng, P., et al. (2017) Mechanisms of Resistance to Anti-EGFR Therapy in Colorectal Cancer. Oncotarget, 8, 3980-4000. [Google Scholar] [CrossRef] [PubMed]
[54] Kopetz, S., Guthrie, K.A., Morris, V.K., Lenz, H.J., Magliocco, A.M., Maru, D., et al. (2021) Randomized Trial of Irinotecan and Cetuximab with or without Vemurafenib in BRAF-Mutant Metastatic Colorectal Cancer (SWOG S1406). Journal of Clinical Oncology, 39, 285-294. [Google Scholar] [CrossRef] 
[55] O’Brien, P. and O’Connor, B.F. (2008) Seprase: An Overview of an Important Matrix Serine Protease. Biochimica et Biophysica Acta, 1784, 1130-1145. [Google Scholar] [CrossRef] [PubMed]
[56] Wen, Y., Wang, C.T., Ma, T.T., Li, Z.Y., Zhou, L.N., Mu, B., et al. (2010) Immunotherapy Targeting Fibroblast Activation Protein Inhibits Tumor Growth and Increases Survival in a Murine Colon Cancer Model. Cancer Science, 101, 2325-2332. [Google Scholar] [CrossRef] [PubMed]
[57] Hofheinz, R.D., Al-Batran, S.E., Hartmann, F., Hartung, G., Jäger, D., Renner, C., et al. (2003) Stromal Antigen Targeting by a Humanised Monoclonal Antibody: An Early Phase II Trial of Sibrotuzumab in Patients with Metastatic Colorectal Cancer. Onkologie, 26, 44-48. [Google Scholar] [CrossRef] [PubMed]

为你推荐